MMS – Credit Suisse rates the stock as Outperform
McMillan Shakespeare's latest update cites higher recovery in novated lease sales and growth in Plan Partners as reasons for experiencing better than expected conditions. The outlook for FY22 is positive, suggests Credit Suisse. Outperform with target rising to $14 from $12.85.
Read More